The chemical class designated as PLP-J Activators encompasses a diverse array of compounds that influence the activity of the protein PLP-J. This protein is a member of the prolactin family, and its regulation is generally understood within the context of endocrine signaling pathways. The activators in this class are not uniform in structure or primary function; instead, they share the common attribute of being able to alter the biological activity of PLP-J through various mechanisms related to prolactin regulation. The mechanisms through which this class of chemicals acts involve modulation of the neuroendocrine system, which can ultimately influence the secretion or action of prolactin and related proteins.
The compounds that are categorized as PLP-J Activators can operate by either augmenting or diminishing the levels of prolactin within the body. Some activators achieve this by interacting with dopamine receptors, which play a critical role in the inhibitory regulation of prolactin secretion. By mimicking or blocking the action of dopamine at these receptors, these activators can modulate the balance of prolactin and potentially influence the activity of PLP-J. Other members of this chemical class exert their effects through interactions with hormonal pathways, such as the release of thyrotropin-releasing hormone or the action of estrogen, which are known to regulate prolactin production. Additionally, certain activators in this class may influence prolactin levels by affecting neurotransmitter reuptake mechanisms, thereby indirectly impacting the neuroendocrine system and altering PLP-J activity. Collectively, these compounds, through their diverse actions on prolactin regulation, constitute the PLP-J Activator chemical class, and each member can contribute to changes in the activity of the PLP-J protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bromocriptine | 25614-03-3 | sc-337602A sc-337602B sc-337602 | 10 mg 100 mg 1 g | $57.00 $265.00 $567.00 | 4 | |
A dopamine D2 receptor agonist that inhibits prolactin secretion by mimicking dopamine's effect, which could possibly activate Prl3c1 through similar mechanisms of reduced prolactin competition. | ||||||
Cabergoline | 81409-90-7 | sc-203864 sc-203864A | 10 mg 50 mg | $300.00 $1055.00 | ||
This dopamine receptor agonist is used to inhibit prolactin secretion and could possibly activate Prl3c1 by decreasing prolactin-mediated regulatory effects. | ||||||
Levodopa | 59-92-7 | sc-205372 sc-205372A | 5 g 25 g | $54.00 $171.00 | 9 | |
As a precursor to dopamine, it could possibly activate Prl3c1 by increasing dopamine levels and thus reducing prolactin secretion. | ||||||
Metoclopramide | 364-62-5 | sc-358363 | 100 g | $465.00 | 1 | |
It can increase prolactin levels due to its antagonistic effects on dopamine receptors, which could possibly activate Prl3c1 by enhancing overall prolactin activity. | ||||||
Domperidone | 57808-66-9 | sc-203032 sc-203032A | 50 mg 250 mg | $61.00 $287.00 | 2 | |
By preventing dopamine from inhibiting prolactin release, it could possibly activate Prl3c1 by increasing prolactin levels and altering the hormonal milieu. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Chemicals that mimic estrogen could possibly activate Prl3c1 by stimulating prolactin production and modifying intracellular signaling pathways. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
An antipsychotic that could possibly activate Prl3c1 by increasing prolactin levels through dopamine receptor blockade. | ||||||
Fluoxetine hydrochloride | 56296-78-7 | sc-201125 sc-201125A sc-201125B sc-201125C | 50 mg 250 mg 1 g 5 g | $77.00 $213.00 $407.00 $849.00 | 14 | |
These may raise prolactin levels by increasing synaptic serotonin, which could possibly activate Prl3c1 by influencing prolactin secretion indirectly. | ||||||